Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224000 · ClinicalTrials.gov registry record · Phase 2
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
A Phase 2 study of Oropharyngeal Cancer and Malignant Neoplasms of Lip Oral Cavity and Pharynx, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT03224000: Active Phase 2 study of Oropharyngeal Cancer and Malignant Neoplasms of Lip Oral Cavity and Pharynx, sponsored by M.D. Anderson Cancer Center.
NCT03224000 is a Phase 2 study of Oropharyngeal Cancer and Malignant Neoplasms of Lip Oral Cavity and Pharynx that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 90 participants, below the 186-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03224000, a Phase 2 study of Oropharyngeal Cancer and Malignant Neoplasms of Lip Oral Cavity and Pharynx, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to compare the use of MRI simulations to plan different doses of intensity modulated radiotherapy (IMRT) to the standard IMRT dose in patients with low risk human papilloma virus positive oropharyngeal cancer. This is an investigational study. MRI simulations and radiation therapy are delivered using FDA-approved and commercially available methods. The use of MRI imaging to plan the dose is investigational. Up to 90 participants will be enrolled in this study. All will take part at MD Anderson.
Primary Outcome
Relapse defined as reappearance of tumor after complete response. If possible, relapse confirmed by biopsy.
Conditions Studied
Interventions
- PROCEDURE Modified Barium Swallow (MBS)
- BEHAVIORAL Swallowing Questionnaire
- BEHAVIORAL Symptom Questionnaire
- PROCEDURE Video-Strobe Procedure
- PROCEDURE MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03224000 still lists
NCT03224000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 186-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (52% lower).
The record links to 2 conditions, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Modified Barium Swallow (MBS) is the first listed.
NCT03224000 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03224000 about?
NCT03224000 is a clinical study titled "Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer". The goal of this clinical research study is to compare the use of MRI simulations to plan different doses of intensity modulated radiotherapy (IMRT) to the standard IMRT dose in patients with low risk human papilloma virus positive oropharyngeal cancer. This is an investigational study. MRI simulat...
What is the current status of trial NCT03224000?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2018-01-17. Estimated completion is 2026-12-31.
What conditions does trial NCT03224000 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer, Malignant Neoplasms of Lip Oral Cavity and Pharynx.
What interventions are being tested in trial NCT03224000?
The interventions under investigation include: Modified Barium Swallow (MBS) (PROCEDURE), Swallowing Questionnaire (BEHAVIORAL), Symptom Questionnaire (BEHAVIORAL), Video-Strobe Procedure (PROCEDURE), MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning (PROCEDURE).
Who is sponsoring clinical trial NCT03224000?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224000 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03224000's enrollment target sits among peer trials
90 11th of 25 higher than 15 of 25 other Oropharyngeal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharyngeal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
RECRUITING · Phase 2
-
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI